CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

被引：0
|
作者：
Wang, Michelle
Zhao, Xiaohong
Jiang, Huijuan
Yan, Joy Catherine
Sotomayor, Eduardo
Shain, Kenneth H.
Shah, Bijal
Tao, Jianguo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Mantle cell lymphoma (MCL): What's new?
    Gascoyne, R
    ANNALS OF ONCOLOGY, 2005, 16 : 48 - 48
  • [22] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Balasubramanian, Sriram
    Schaffer, Michael
    Deraedt, William
    Davis, Cuc
    Stepanchick, Emily
    Aquino, Regina
    Yuan, Zhilong
    Kranenburg, Britte
    Avivi, Irit
    Dreyling, Martin
    Rule, Simon
    Wang, Michael
    Zhuang, Sen Hong
    Rizo, Aleksandra
    Lenz, Georg
    BLOOD, 2014, 124 (21)
  • [23] The molecular context of vulnerability for CDK9 suppression in melanoma
    Guhan, S. M.
    Shaughnessy, M.
    Rajadurai, A.
    Kumar, R.
    Ji, Z.
    Gray, N.
    Tsao, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S12 - S12
  • [24] CDK9: Therapeutic Perspective in HCC Therapy
    Borowczak, Jedrzej
    Szczerbowski, Krzysztof
    Stec, Ewa
    Grzanka, Dariusz
    Szylberg, Lukasz
    CURRENT CANCER DRUG TARGETS, 2020, 20 (05) : 318 - 324
  • [25] CDK9 as a potential therapeutic target in sarcomas
    Matsumura, Yuta
    Umehara, Hiroki
    Oishi, Jun
    Siddiqui, Adam
    Foulks, Jason M.
    Yamamoto, Setsuko
    Warner, Steven L.
    CANCER RESEARCH, 2022, 82 (12)
  • [26] CDK9 as an Appealing Target for Therapeutic Interventions
    Eyvazi, Shirin
    Hejazi, Mohammad Saeid
    Kahroba, Homan
    Abasi, Mozghan
    Zamiri, Reza Eghdam
    Tarhriz, Vahideh
    CURRENT DRUG TARGETS, 2019, 20 (04) : 453 - 464
  • [27] Ibrutinib for the treatment of mantle cell lymphoma
    Shah, Nimish
    Hutchinson, Claire
    Rule, Simon
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 521 - 531
  • [28] Ibrutinib for the Treatment of Mantle Cell Lymphoma
    Herrera, Alex F.
    Jacobsen, Eric D.
    CLINICAL CANCER RESEARCH, 2014, 20 (21) : 5365 - 5371
  • [29] Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma
    Colomer, Dolors
    Campo, Elias
    CANCER CELL, 2014, 25 (01) : 7 - 9
  • [30] Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
    J Lemke
    S von Karstedt
    M Abd El Hay
    A Conti
    F Arce
    A Montinaro
    K Papenfuss
    M A El-Bahrawy
    H Walczak
    Cell Death & Differentiation, 2014, 21 : 491 - 502
12345